Search Results for "Immunotherapy"

Checkpoint Inhibitors: Entering a New Era in Cancer Treatment

Using two agents that target two different receptors more than doubles length of survival for advanced melanoma than a single agent alone, researchers reported at the 2021 American Society of Clinical Oncology annual meeting.

The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient’s cancer treatment. This is the Spanish version.

Discover what you can learn with our compilation of resources to help expand your education around immuno-oncology. Explore books, clinical practice resources, learning tools, podcasts, videos, and more. 

Growing evidence suggests that the gut microbiome, a diverse and complex mix of microorganisms and their metabolites, is closely linked to the immune system, and researchers are studying whether modulating the gut microbiome affects cancer immunotherapy treatment outcomes. In particular, probiotics—which are flora typically obtained through dietary sources such as yogurt and fermented foods or via supplemental forms—are gaining prominence as a potential strategy to modulate the gut microbiome during cancer treatment.

Completing up to a year of pembrolizumab immunotherapy after surgical resection of stage IIB or IIC melanoma decreases patients’ risk for disease recurrence or death by 35%, according to study findings presented at the European Society for Medical Oncology 2021 annual meeting. The new findings led the U.S. Food and Drug Administration to expand its approval of pembrolizumab to use as adjuvant therapy in both adults and children aged 12 and older with early-stage melanoma.

ONS video on CAR T-cell therapy. 

Watch this ONS interview with Megan Harvey, clinical nurse at the Hospital of the University of Pennsylvania, on CAR T-cell therapy.